ESE recommendation on CRH shortage: scope of the problem and how to address it
The main global supplier of CRH has stopped manufacturing, and the unavailability of stock duration is currently unknown. This imposes a threat on the availability of CRH worldwide, hence alternative diagnostic approaches are required, particularly for the work-up of ACTH-dependent Cushing’s syndrome, where CRH is most useful. ESE is providing a recommendation in the document below regarding this issue.
Position Statements , ESE News , Adrenal and Cardiovascular Endocrinology , Pituitary and Neuroendocrinology , Clinicians , Early Careers , (Allied) Health Professionals , Nurses , Researchers , Patients , Public ,